12 stories found
The U.S. Food and Drug Administration has approved a new once-daily oral medication for advanced pancreatic cancer, marking a significant clinical breakthrough that nearly doubled patient survival rates in trials. The approval has prompted analysts to raise price targets for associated biotechnology firms.
JPMorgan has adjusted its price target upwards for Xenon Pharmaceuticals (XENE), reflecting a potentially more optimistic view on the company's future performance.
Xenon Pharmaceuticals Inc. is reportedly eyeing a significant market opportunity estimated to be worth $2 billion.
Dianthus Therapeutics has announced the pricing of its upsized public offering, raising $625 million with shares priced at $81 each.
This article provides a summary of the key points from Xenon Pharmaceuticals' second-quarter earnings call.
A fund has made a new $22 million investment in Xenon Pharmaceuticals, anticipating an upcoming FDA filing.
An insider at Xenon Pharma has sold $78,000 worth of shares, coinciding with a substantial 55% increase in the company's stock price.
Several stocks, including Hims & Hers Health, oil stocks, and Live Nation Entertainment, are making significant moves in premarket trading, with Hims & Hers specifically upgraded to Buy from Hold by Needham.
Xenon Pharmaceuticals expects to submit its AZK New Drug Application later this quarter and has secured funding to support its operations until 2029.
Xenon Pharmaceuticals expects to submit its New Drug Application (NDA) for AZK in the third quarter of 2026, with a projected launch timing at the end of 2027 or early 2028.
Xenon Pharmaceuticals has announced a proposed public offering, which typically involves selling new shares to raise capital for company operations or expansion.